US-based immuno-oncology company TCR2 Therapeutics Inc has completed a series B venture financing round co-led by 6 Dimensions Capital and Curative Ventures.

The company has raised $125m from the round, which also saw participation of new as well as existing investors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The proceeds are intended to be used for advancing two TRuC-T cell programs through human proof-of-concept.

DBV Technologies SA has announced the pricing for its planned private placement of ordinary shares.

The company will place 2,135,737 shares priced at €34.71 ($42.68) a share as part of the placement to raise €74.13m ($91.16m) in gross proceeds.

Underwriters have been granted a 30-day option to purchase up to an additional 529,162 ordinary shares.

Proceeds are intended to be used to fund the development and commercialisation of Viaskin Peanut and advance development of other product candidates.

Part of proceeds will also be used for working capital and general corporate purposes.

“The offering includes 8.5 million shares priced at $41.50 a share to raise $352.8m in gross proceeds.”

Based in France, DBV Technologies is a biopharmaceutical company.

US-based biopharmaceutical company Arena Pharmaceuticals Inc has announced the pricing for its underwritten public offering of common stock shares.

The offering includes 8.5 million shares priced at $41.50 a share to raise $352.8m in gross proceeds.

Underwriters have been granted a 30-day option to purchase up to 1.275 million additional shares at the same price, less underwriter discounts, and commissions.

Proceeds are intended to be used for clinical and pre-clinical development of the company’s drug candidates, and for general corporate purposes.

Xencor Inc has announced the pricing for its proposed underwritten public offering of shares to raise $226.3m in gross proceeds to fund working capital and general corporate purposes.

Priced at $31 a share, the offering includes 7.3 million shares, while underwriters have been granted an option to purchase up to an additional 1.095 million shares to cover over-allotments.

Based in the US, Xencor Inc is a clinical-stage biopharmaceutical company.